Clinical study of Kaixin Changyu granule in the treatment of post-stroke depression

The First Affiliated Hospital of Dalian Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Refer to the Key Points for Diagnosis of Various Cerebrovascular Diseases revised by the Chinese Medical Association to be diagnosed with stroke;
•2. According to the Chinese Classification and Diagnosis of Mental Disorders-Third Edition (CCMD-III), subjects diagnosed with secondary mild to moderate depression, Hamilton Depression Scale (HAMD-17) 17 items Score between 7 and 24 points;
•3. The age of the subject is between 40 and 80 years old, regardless of gender;
•4. Patients who were diagnosed with depression for the first time after stroke (diagnosed as PSD within 6 months after stroke);
•5. No history of mental illness or family history of mental illness before stroke;
•6. Normal consciousness can cooperate with various examinations, no aphasia or severe cognitive impairment, mental status examination (MMSE score)> 17 points;
•7. Liver and kidney function tests are normal;
•8. Be able to provide a voluntary signed informed consent form.

•1. Participate in any other clinical trials or take hormones and psychotropic drugs within the last 1 month;
•2. Unstable vital signs, poor control of underlying diseases, or serious systemic diseases such as heart disease or malignant tumors;
•3. Allergic to the ingredients of Kaixin Changyu Granules;
•4. Pregnant or lactating women;
•5. Magnetic resonance contraindications.

发起方

The First Affiliated Hospital of Dalian Medical University